Key Takeaway: The article discusses an update from Cognition Therapeutics regarding the MAGNIFY Trial enrollment and their ongoing efforts related to dry Age-related Macular Degeneration (AMD). However, the content primarily redirects to third-party sites and does not provide specific details about the trial or the company's work.
Price reaction · baseline $1.93 (2024-01-05 close) · clean, no other CGTX news in the window
day 0 close · peak
+3.1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.